Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
10x Genomics (TXG) reported $183.98 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 17.8%. EPS of -$0.41 for the same period compares to -$0.15 a year ago.
The reported revenue represents a surprise of +0.03% over the Zacks Consensus Estimate of $183.93 million. With the consensus EPS estimate being -$0.36, the EPS surprise was -13.89%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Consumables: $140.31 million compared to the $135.33 million average estimate based on two analysts. The reported number represents a change of +6.6% year over year.
Revenues- Services: $5.27 million compared to the $4.95 million average estimate based on two analysts. The reported number represents a change of +128.7% year over year.
Revenues- Instruments: $38.40 million compared to the $36.98 million average estimate based on two analysts. The reported number represents a change of +71.9% year over year.
View all Key Company Metrics for 10x Genomics here>>>
Shares of 10x Genomics have returned +14.8% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
10x Genomics (TXG) : Free Stock Analysis Report
